Share this entry
Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation
By: News Feed | Last updated: 2nd May 2019 | In: Haematology, Targeted Therapies, US FDA Onc\Haem Approvals
Abbott, acute myeloid leukaemia, Agios Pharmaceuticals, AML, HSCT, IDH1, ivosidenib, leukaemia, RealTime IDH1 Assay, Tibsovo
On the 2nd of May 2 2019, the FDA approved ivosidenib (Tibsovo®, Agios) as treatment for newly-diagnosed acute myeloid leukaemia (AML) patients ≥75 years old and AML patients with comorbidities precluding intensive induction chemotherapy. Patients should harbour a susceptible IDH1 mutation, as per the FDA-approved Abbott RealTime™ IDH1 Assay, to be legible for ivosidenib treatment.
Phase 1 data
The FDA approval was based on the phase 1, open-label, single-arm, multicentre AG120-C-001 trial (NCT02074839) investigating single-agent ivosidenib in 28 newly-diagnosed AML patients aged ≥75 years (median age 77 years [range, 64-87]) or patients with one or more comorbidities including a baseline Eastern Cooperative Oncology Group (ECOG) performance status ≥2, severe cardiac or pulmonary disease, hepatic impairment with bilirubin >1.5 times the upper limit of normal (ULN), or creatinine clearance < 45 mL/min. Moreover. all patients were found to harbour an IDH1 mutation by the Abbott RealTime™ IDH1 Assay. Twenty-two (79%) had therapy-related AML or AML with myelodysplasia-related changes. Patients received ivosidenib-treatment until progression disease, the development of unacceptable toxicity, or haematopoietic stem cell transplantation (HSCT). The efficacy endpoints included the rate of complete remission (CR) or CR with partial haematological recovery (CRh), the duration of the CR/CRh response, and the conversion-rate from transfusion-dependence to -independence.
Of the 28 enrolled patients, 12 (42.9%; 95% CI, 24.5-62.8) had a CR or CRh. Seven (41.2%) of the 17 transfusion-dependent patients became transfusion-independent for 8 weeks or longer. Two (7%) of the 28 patients underwent HSCT following ivosidenib.
Adverse reactions in at least 25% of patients included diarrhoea, fatigue, oedema, decreased appetite, leukocytosis, nausea, arthralgia, abdominal pain, dyspnoea, differentiation syndrome and myalgia. The ivosidenib prescribing information contains a Boxed Warning about the risk of life-threatening or fatal differentiation syndrome.
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2019 MediPaper Medical Communications Ltd.